Abstract
Alprazolam is a triazolobenzodiazepine which has been reported to be effective in the treatment of panic disorder (Ballenger et al., 1988). Although the mechanism of action of alprazolam in panic disorder has not been determined, the drug has been shown to decrease noradrenergic activity with the down-regulation of post-synaptic β-receptors in brain slices and animal studies (Charney et al., 1986). We have shown that alprazolam-treated patients with panic disorder and agoraphobia have an increase in the number of high-affinity platelet-tritiated imipramine binding sites which significantly correlates with improvement in symptoms of anxiety, depression and a decrease in the number of panic attacks (Pecknold et al., 1989). Platelet [3H]-imipramine binding sites appear to be associated with the uptake of serotonin (Langer et al., 1980). As it has been reported that serotonin may be involved in panic disorder (Pecknold, 1990) and that serotonergic agents such as clomipramine (Johnson et al., 1988) zimeldine (Evans et al., 1986) and fluvoxamine (den Boer and Westenberg, 1988) are effective in the treatment of panic disorder, the use of imipramine binding as a predictor of response to effective treatment is of major clinical interest.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
References
Ballenger, J. C., Burrows, G. D., DuPont, R. L. (Jr), Lesser, I. M., Noyes, R. (Jr), Pecknold, J. C., Rifkin, A. and Swinson, R. (1988). Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch. Gen. Psychiatry, 45, 413–22.
Baron, M., Barkai, A., Gruen, R., Kowalik, S. and Quitkin, F. (1983). [3H]-imipramine platelet binding sites in unipolar depression. Biol. Psychiat., 18, 1403–9.
Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D. and Zarifian, E. (1980). Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science, 209, 303–5.
Charney, D. S., Breier, A., Jatlow, P. I. and Henenger, G. R. (1986). Behavioural, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psychopharmacology, 88, 133–40.
Coppen, A., Swade, C. and Wood, K. (1978). Platelet 5-hydroxytryptamine accumulation in depressive illness. Clin. Chim. Acta, 87, 165–8.
Den Boer, J. A. (1988). Serotonergic Mechanisms in Anxiety Disorders, CIP—Gegevens Koninklijke Bibliotheek, Den Haag.
Den Boer, J. A. and Westenberg, H. G. (1988). Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline. Int. Clin. Psychopharmacol., 3, 59–74.
Eriksson, E. (1987). Brain neurotransmission in panic disorder. Acta Psychiatr. Scand., 76, 31–7.
Eriksson, E., Carlsson, M., Nilsson, C. and Soderpalm, B. (1986). Does alprazolam, in contrast to diazepam, activate alpha-adrenoceptors involved in the regulation of rat growth hormone secretion? Life Sciences, 38, 1491–8.
Evans, L., Kennedy, J., Schneider, P. and Hoey, H. (1986). Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatr. Scand., 73, 49–53.
Hamilton, M. (1959). The assessment of anxiety states by rating. Br. J. Med. Psychol., 32, 50–5.
Hamilton, M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatry, 23, 56–62.
Hrdina, P. (1984). Differentiation of two components of specific [3H]-imipramine binding in rat brain. Eur. J. Pharmacol., 102, 481–8.
Ieni, J. R., Zukin, S. R. and Van Praag, H. M. (1985). Human platelets possess multiple 3H-imipramine binding sites. Eur. J. Pharmacol., 106, 669–72.
Innis, R. B., Charney, D. S. and Heninger, G. R. (1987). Differential 3H-imipramine binding in patients with panic disorder and depression. Psychiatry Res., 21, 33–41.
Johnson, D. G., Troyer, I. E. and Whitsett, S. E. (1988). Clomipramine treatment of agoraphobic women. Arch. Gen. Psychiatry, 45, 453–9.
Kahn, R. S. and Westenberg, H. G. (1985). L-5-Hydroxytryptophan in the treatment of anxiety disorders. J. Affective Dis., 8, 197–200.
Kahn, J. P., Stevenson, E., Topol, P. and Klein, D. F. (1986). Agitated depression, alprazolam, and panic anxiety. Am. J. Psychiatry, 143, 1172–3.
Klerman, G. L. (1988). Overview of the cross-national collaborative panic study. Arch. Gen. Psychiatry, 45, 407–12.
Langer, S. Z. and Briley, M. S. (1981). High affinity [3H]-imipramine binding: a new biological tool for studies in depression. Trends Pharmacol. Sci., 4, 98–31.
Langer, S. Z., Raisman, R. and Briley, M. S. (1980). Stereoselective inhibition of 3H-imipramine binding by antidepressant drugs and their derivatives. Eur. J. Pharmacol., 64, 89–90.
Lewis, D. A. and McChesney, C. (1985). Tritiated imipramine binding distinguishes among subtypes of depression. Arch. Gen. Psychiatry, 42, 485–8.
Marks, I. M. and Mathews, A. M. (1979). Brief standard self-rating for phobic patients. Behav. Res. Ther., 17, 263–7.
Meltzer, H. Y., Ramesh, C. A., Arora, R. C., Baber, R. and Tricou, B. J. (1981). Serotonin uptake in blood platelets of psychiatric patients. Arch. Gen. Psychiatry, 38, 1322–6.
Palkovitcs, M., Raisman, R., Briley, M. S. and Langer, S. Z. (1981). Regional distribution of [3H]-imipramine binding in rat brain. Brain Res., 210, 493–8.
Paul, S. M., Rehavi, M., Skolknick, K. P. and Goodwin, F. K. (1980). Demonstration of specific ‘high affinity’ binding sites for 3H-imipramine on human platelets. Life Sci., 26, 953–9.
Pecknold, J. C. (1990). Serotonin abnormalities in panic disorder. In Ballenger, J. (ed.), Neurobiology of Panic Disorder, Liss, New York, 121–42.
Pecknold, J. C., Chang, H., Fleury, D., Koszycki, D., Quirion, R., Nair, N. P. V. and Suranyi-Cadotte, B. E. (1987). Platelet imipramine binding in patients with panic disorder and major familial depression. J. Psychiat. Res., 21, 319–26.
Pecknold, J. C., Luthe, L., Chang, H. and Suranyi-Cadotte, B. E. (1989). Imipramine binding in panic disorder patients treated with alprazolam. Presented at the APA Meeting, San Francisco, May 1989.
Pecknold, J. C., McClure, D. J., Appeltaver, L., Allan, T. and Wrzesinki, L. (1982). Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients? Br. J. Psychiatry, 140, 484–90.
Prange, A. J., Wilson, I. G., Lynn, C. W., Alltop, L. B. and Stikeleather, R. A. (1974). L-Tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch. Gen. Psychiatry., 30, 56–62.
Redmond, D. E. (Jr) (1982). Does Clonidine alter anxiety in humans. Trends Pharmacol. Sci., 3, 477–80.
Rehavi, M., Ittah, Y., Rick, K. C., Skolnick, K. P., Goodwin, F. K., and Paul, S. M. (1981). 2-Nitroimipramine: a selective irreversible inhibitor of [3H]-serotonin uptake and [3H]-imipramine binding in platelets. Biochem. Biophys. Res. Comm., 99, 954–9.
Reith, M. E. A., Sershen, H., Allen, D. and Lajtha, A. (1983). High and low-affinity binding of 3H-imipramine in mouse cerebral cortex. J. Neurochem., 40, 389–95.
Roy-Byrne, P. P. and Uhde, T. W. (1985). Panic disorder and major depression: biological relationships. Psychopharmacol. Bull., 21, 551–54.
Schneider, L. S., Munjack, D., Severson, J. A. and Palmer, R. (1987). Platelet 3H-imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks. Biol. Psychiatry, 22, 59–66.
Sheehan, D. V., Coleman, J. H., Greenblatt, D. J., Jones, K. J., Levine, P. H., Orsulak, P. J., Peterson, M., Schildkraut, J. J., Uzogara, E. and Watkins, D. (1984). Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J. Clin. Psychopharmacol., 4, 66–75.
Spitzer, R. L. and Williams, J. B. W. (1983). Structured clinical interview for DSM-III-Upjohn version (SCID-UP, 12/15/83), Biometrics Research Division, New York State Psychiatric Institute, New York.
Tuomisto, J., Tukiainen, E. and Ahlfors, U. G. (1979). Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients with endogenous depression. Psychopharmacology (Berlin), 65, 141–7.
Turmel, A. and De Montigny, C. (1984). Sensitization of rat forebrain neurons to serotonin by adinazolam, an antidepressant triazolobenzodiazepine. Eur. J. Pharmacol., 99, 241–4.
Uhde, T. W., Berrettini, W. H., Roy-Byrne, P. P., Boulanger, J. P. and Post, R. M. (1987). 3H-imipramine binding in patients with panic disorder. Biol. Psychiatry, 22, 52–8.
Wood, P. L. and Peloguin, A. (1982). Increases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology, 21, 349–54.
Wood, P. L., Suranyi-Cadotte, B. E., Nair, N. P. V., LaFaille, F. and Schwartz, G. (1983). Lack of association between 3H-imipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients. Neuropharmacology, 22, 1211–14.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1991 Macmillan Publishers Limited
About this chapter
Cite this chapter
Pecknold, J.C., Luthe, L., Suranyi-Cadotte, B. (1991). Platelet Imipramine Binding Bmax Predicts Response to Anxiety in Alprazolam-Treated Panic Disorder Patients. In: Briley, M., File, S.E. (eds) New Concepts in Anxiety. Palgrave, London. https://doi.org/10.1007/978-1-349-11847-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-349-11847-2_12
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-11849-6
Online ISBN: 978-1-349-11847-2
eBook Packages: EngineeringEngineering (R0)